These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33999591)

  • 1. SARS-CoV-2 infection in a patient with psoriasis treated with risankizumab.
    Huang C; Chen T
    Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999591
    [No Abstract]   [Full Text] [Related]  

  • 2. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic.
    Hansel K; Zangrilli A; Bianchi L; Peris K; Chiricozzi A; Offidani A; Diotallevi F; Fargnoli MC; Esposito M; Amerio P; Gualdi G; Bianchi L; Stingeni L
    J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):e169-e170. PubMed ID: 33080112
    [No Abstract]   [Full Text] [Related]  

  • 3. COVID-19 infection on IL-23 inhibition.
    Wang CJ; Truong AK
    Dermatol Ther; 2020 Nov; 33(6):e13893. PubMed ID: 32584451
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19 and systemic therapies in psoriasis: experience of a tertiary hospital in Madrid.
    Fulgencio-Barbarin J; Puerta-Peña M; Ortiz-Romero P; García-Donoso C; Rivera-Diaz R
    Int J Dermatol; 2020 Nov; 59(11):1425-1426. PubMed ID: 32886364
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China.
    Zhao L; Du H; Alamgir M; Yang J; Miao X; Jiang B; Xia Y; Lou Y; Wang Y; Shen C; Zhu J; Chung WH; Li Y; Tao J
    Eur J Dermatol; 2020 Dec; 30(6):738-740. PubMed ID: 33459264
    [No Abstract]   [Full Text] [Related]  

  • 6. Risankizumab: First Global Approval.
    McKeage K; Duggan S
    Drugs; 2019 Jun; 79(8):893-900. PubMed ID: 31098898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature.
    McDonald J; Maliyar K; Gooderham MJ
    Skin Therapy Lett; 2020 May; 25(3):1-4. PubMed ID: 32510689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.
    Witjes H; Khatri A; Diderichsen PM; Mandema J; Othman AA
    Clin Pharmacol Ther; 2020 Feb; 107(2):435-442. PubMed ID: 31502263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients.
    Khatri A; Suleiman AA; Polepally AR; Othman AA
    Clin Pharmacol Ther; 2020 Feb; 107(2):378-387. PubMed ID: 31355921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients.
    Pang Y; Khatri A; Suleiman AA; Othman AA
    Clin Pharmacokinet; 2020 Mar; 59(3):311-326. PubMed ID: 31758502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
    Visvanathan S; Baum P; Vinisko R; Schmid R; Flack M; Lalovic B; Kleiner O; Fuentes-Duculan J; Garcet S; Davis JW; Grebe KM; Fine JS; Padula SJ; Krueger JG
    J Allergy Clin Immunol; 2019 Jun; 143(6):2158-2169. PubMed ID: 30578873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risankizumab for the treatment of psoriasis.
    Gu C; Yang J
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
    [No Abstract]   [Full Text] [Related]  

  • 14. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
    N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alopecia universalis improvement following risankizumab in a psoriasis patient.
    Martora F; Villani A; Ocampo-Garza SS; Fabbrocini G; Megna M
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e543-e545. PubMed ID: 35181958
    [No Abstract]   [Full Text] [Related]  

  • 17. Risankizumab for the treatment of moderate to severe psoriasis.
    Chiricozzi A; Antonioli L; Panduri S; Fornai M; Romanelli M; Blandizzi C
    Expert Opin Biol Ther; 2019 Jan; 19(1):1-8. PubMed ID: 30462554
    [No Abstract]   [Full Text] [Related]  

  • 18. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
    Li W; Ghamrawi R; Haidari W; Feldman SR
    Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
    [No Abstract]   [Full Text] [Related]  

  • 19. Risankizumab in moderate-to-severe plaque psoriasis.
    Serrano L; Maloney V; Gordon KB
    Immunotherapy; 2019 Nov; 11(16):1357-1370. PubMed ID: 31578912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities.
    Rob F; Rozsypal H
    Dermatol Ther; 2022 Mar; 35(3):e15277. PubMed ID: 34923721
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.